Stay updated on Ravulizumab Study in LN/IgAN Clinical Trial
Sign up to get notified when there's something new on the Ravulizumab Study in LN/IgAN Clinical Trial page.

Latest updates to the Ravulizumab Study in LN/IgAN Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoNo Change Detected
- Check19 days agoChange DetectedThe page now reflects revision label v3.5.0 and the previous label v3.4.3 has been removed.SummaryDifference0.0%

- Check26 days agoChange DetectedThe page revision was updated to v3.4.3, replacing the previous v3.4.2.SummaryDifference0.0%

- Check55 days agoChange DetectedRevision updated to v3.4.2; the lapse-in-government funding notice and the prior revision reference (v3.4.1) were removed.SummaryDifference0.3%

- Check62 days agoChange DetectedAdded a government funding notice about site status and that the NIH Clinical Center is open; updated Revision: v3.4.1 and removed Revision: v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check69 days agoChange DetectedResults for SANCTUARY (NCT04564339) were posted on 2026-01-22, including Week 26 and Week 50 proteinuria and eGFR outcomes for LN and IgAN cohorts; several previously listed result metrics were removed.SummaryDifference3%

- Check83 days agoChange DetectedThe page now displays 'Results Submitted' instead of 'No Results Posted' and the revision version updated from v3.3.3 to v3.3.4.SummaryDifference0.1%

Stay in the know with updates to Ravulizumab Study in LN/IgAN Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ravulizumab Study in LN/IgAN Clinical Trial page.